SLC26A9

Across TCGA pan-cancer cohorts, SLC26A9 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC26A9 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SLC26A9 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated SLC26A9 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, UVM, and PRAD are the cancer types where SLC26A9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.980	0.823	.003	32	view →
UVM	OS	Median	II,III,IV	0.218	0.718	.006	24	view →
PRAD	DFS	Median	All	0.085	0.774	.007	6	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLC26A9–UCEC (DFS)

Open the UCEC breakdown →